Moffitt Cancer Center deploys PathAI AISight Dx for AI-powered digital pathology across cancer care programs

Moffitt Cancer Center sought to advance cancer detection and diagnostic accuracy by integrating AI-driven technology into its pathology infrastructure. The center needed a platform that could support laboratory workflow, translational research, clinical trial support, and biopharma collaborations at enterprise scale.

Moffitt deployed PathAI's AISight Dx, a cloud-native digital pathology image management system, across its pathology programs. The platform combines enterprise-scale slide management, viewing, and collaboration with AI integration. The multi-year strategic collaboration also establishes a framework for joint research programs, real-world multimodal data collection, and co-development of AI-based diagnostics for precision medicine applications.

The deployment integrates AI-driven technology into clinical oncology to enable faster, more accurate pathologist review. The partnership aims to unlock pathology data and integrate it with imaging and clinical insights to deliver personalized patient care, and to lay groundwork for next-generation oncology research and future AI-powered care models.

• Integrating AI into digital pathology at a major cancer center requires a multi-year strategic framework covering clinical, research, and biopharma use cases simultaneously.
• FDA-cleared platforms (AISight Dx has FDA clearance for primary diagnosis) reduce regulatory friction when deploying AI for clinical use in the US.
• Combining slide management, AI, and multimodal data integration positions pathology as a hub for precision medicine rather than a siloed diagnostic function.